Cartesian Therapeutics, Inc.

RNAC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014
Operating Activities
Net Income $-65.3M $-36.2M $-25.2M $-12.9M
Depreciation & Amortization
Depreciation $750.0K $802.0K $1.0M $864.0K
Amortization
Stock-Based Compensation $4.1M
Net Cash from Operating Activities $-52.0M $-19.8M $-22.5M $-12.7M
Investing Activities
Capital Expenditures $733.0K $586.0K $1.2M $227.0K
Business Acquisitions
Net Cash from Investing Activities $-2.1M $-22.1M $-4.7M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $66.0M $67.7M $43.9M
Net Change in Cash $12.0M $26.3M $15.7M $8.5M
Free Cash Flow $-52.8M $-20.3M $-23.6M $-12.9M
← Newer Page 2 of 2 Older →